Omega-3 polyunsaturated fatty acids for major depressive disorder.
Kuan-Pin Su, 왕성민, 배치운
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 201312
62
Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS)
장세헌, 정성원, 배치운, 포트랜드, 넬슨, 파트카
JOURNAL OF AFFECTIVE DISORDERS, 201312
63
Comment on: the relationship between statins and depression: a review of the literature.
배치운
EXPERT OPINION ON PHARMACOTHERAPY, 201312
64
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole: Distinctive Clinical Characteristics of 5 Novel Atypical Antipsychotics.
왕성민, 한창수, 이수정, 파트카, 마산드, 배치운
CLINICAL NEUROPHARMACOLOGY, 201311
66
Curcumin as an Add-On to Antidepressive Treatment: A Randomized, Double-Blind, Placebo-Controlled, Pilot Clinical Study
배치운
CLINICAL NEUROPHARMACOLOGY, 201311
67
Oxidative/nitrosative stress and antidepressants:Targets for novel antidepressants
이승엽, 이수정, 한창수, Ashwin A. Patkar, Prakash S. Masand, 배치운
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 201310
68
An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features.
서호준, 이병철, 석정호, 전홍진, 백종우, 김원, 곽경필, 한창수, 이경욱, 배치운
PHARMACOPSYCHIATRY, 201309
69
Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: A 6-Week prospective, open-label, multicenter study
전덕인, 김도훈, 서호준, 권영준, 김문두, 양종철, 서호석, 민경준, 배치운, 박원명
CLINICAL NEUROPHARMACOLOGY, 201309
70
How much to worry about the FDA warning in the use of citalopram?